Abstracts Archive - Page 2202 of 2607 - ACR Meeting Abstracts

Abstract Number: 476 • 2014 ACR/ARHP Annual Meeting
Medium-Term Safety of TNF-Alpha Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials
Lucile Poiroux¹, Yannick Allanore², Andre Kahan³ and Jerome Avouac⁴, ¹Rhumatologie A, Cochin Hospital, Paris, France, ²Rheumatology, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, ³Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁴Cochin Hospital, Paris, France
Background/Purpose: TNF-a inhibitors have changed the prognosis of rheumatoid arthritis (RA). The number of molecules and the time of exposure have increased. However, few studies…
Abstract Number: 475 • 2014 ACR/ARHP Annual Meeting
Risk Analysis of a First Adverse Event and Recurrent Infections during Biological Therapy in Chronic Inflammatory Arthritis
G. Avila¹, Arnald Alonso¹, Andrea Pluma-Sanjurjo², Carolina Diaz², Roxana Juverdeanu², María América López-Lasanta¹ and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose Biological therapies (BT) have significantly improved the prognosis of chronic inflammatory arthritis (CIA) patients. Although they are characterized by a good safety profile, the…
Abstract Number: 474 • 2014 ACR/ARHP Annual Meeting
Renacer Study: Assessment of 12-Month Efficacy and Safety of 168 Certolizumabpegol Rheumatoid Arthritis Treated Patients from a Multicenter Retrospective National Study in Spain
Vicente Torrente-Segarra¹, Ana Urruticoechea², Héctor Corominas¹, Amalia Sánchez³, Juan Víctor Tovar⁴, Alejandro Muñoz⁵, Anna Martínez⁶, José Antonio González⁴, Manuel Fernández⁷ and Noelia Vázquez on behalf of RENACER Study Group⁸, ¹Hospital General Hospitalet-Sant Joan Despí Moisès Broggi, Hospitalet Llobregat, Barcelona, Spain, ²Hospital de Can Mises, Ibiza, Spain, ³Hospital Universitario Lucus Augusti, Lugo, Spain, ⁴Hospital General Universitario de Elche, Alicante, Spain, ⁵Hospital Universitario de Valme, Sevilla, Spain, ⁶Hospital La Ribera, Alzira, Valencia, Spain, ⁷Hospital Universitario de Guadalajara, Guadalajara, Spain, ⁸Hospital Universitario de Ceuta, Ceuta, Spain
Background/Purpose: There's scant data of CertolizumabPEGol (CZP) in clinical practice. Study goal: assess efficacy and safety of CZP in RA patients at 3, 6,12-month (m), and…
Abstract Number: 473 • 2014 ACR/ARHP Annual Meeting
Complications of Varicella Zona Virus Infections Are More Frequent in Patients Treated with Biologic Drugs When Combined with Steroids
Jacques Morel¹, Florence Tubach^2,3, Yannick Allanore⁴, Daniel Wendling⁵, Celine Cozic⁶, Emmanuelle Dernis Labous⁷, Eric Legangneux⁸, Thao Pham⁹, Sophie Odoit¹⁰, Isabelle Roitg¹¹, Isabelle Koné-Paut¹², Pierre Quartier¹³, Jean Sibilia¹⁴ and Severine Guillaume Czitrom¹⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ³INSERM, Universite Paris Diderot, Paris, France, ⁴Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁶Rheumatology, CHD la Roche sur Yon, La Roche Sur Yon, France, ⁷Rhumatologie, Ch Du Mans, Le Mans, France, ⁸Rheumatology, Centre Hospitalier Public du Cotentin, 50100, France, ⁹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ¹⁰Dermatology, CHU de la Réunion, Saint Denis, France, ¹¹Hopital De Perpignan, Perpignan, France, ¹²Pediatrics Rheumatology, CHU Bicêtre, Le Kremlin Bicêtre, France, ¹³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁵Ch De Bicetre, Le Kremlin Bicetre Cedex, France
Background/Purpose To assess varicella zona virus (VZV) infection features under biological drugs. Methods A call for observations was sent from april 2013 to april 2014…
Abstract Number: 471 • 2014 ACR/ARHP Annual Meeting
Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan
Toshihisa Kojima¹, Nobunori Takahashi¹, Koji Funahashi², Shuji Asai², Yutaka Yoshioka², Kenya Terabe², Nobuyuki Asai^2,3, Toki Takemoto², Naoki Ishiguro¹, Atsushi Kaneko⁴, Yuji Hirano⁵, Yuichiro Yabe⁶ and Yasuhide Kanayama⁷, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Nagoya Univeristy Hospital, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁵Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁶Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan, ⁷Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Background/Purpose: Many evidences including clinical trials of biologics lead us earlier and more aggressive treatment strategy for patients with rheumatoid arthritis (RA). It is stated…
Abstract Number: 470 • 2014 ACR/ARHP Annual Meeting
Safety Profile of Biologic Agents for Rheumatoid Arhtisitis Treatment after the Complication with Methotrexate-Related Lymphoproliferative Disorder
Shuntaro Saito¹, Yuko Kaneko¹, Katsuya Suzuki¹, Michihide Tokuhira² and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Hematology., Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose Lymphoproliferative disorder (LPD) is a rare complication in patients with rheumatoid arthritis(RA) treated with methotrexate(MTX). Although not a few patients experience exacerbation of RA…
Abstract Number: 469 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study
Andrea Cuervo¹, M. Victoria Hernández¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B…
Abstract Number: 468 • 2014 ACR/ARHP Annual Meeting
Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients
Boulos Haraoui¹, John Wade², Marc de Longueville³, Pauline Ralston⁴ and Jeffrey R. Curtis⁵, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of British Columbia, and Vancouver General Hospital, Vancouver, BC, Canada, ³SA Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁴Giant Professional Ltd, London, United Kingdom, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Despite efficacy of anti-tumor necrosis factors (anti-TNFs) in treating chronic immune conditions, some patients (pts) report serious adverse events (SAEs) highlighting a need to…
Abstract Number: 467 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Rabbit Risk Score for Serious Infections in a UK Anti-TNF Treatment Cohort
Lucia Silva-Fernandez^1,2, Mark Lunt¹, Kath D. Watson¹, . BSRBR Control Centre Consortium¹, Deborah P. Symmons¹, Kimme Hyrich¹ and . On behalf of the BSRBR³, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Rheumatology, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³British Society for Rheumatology, London, United Kingdom
Background/Purpose: Serious infections (SI) are a major concern in patients treated with tumour necrosis factor inhibitors (TNFi). The RABBIT Risk Score (RRS) (1) allows a…
Abstract Number: 466 • 2014 ACR/ARHP Annual Meeting
Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery?
Charlotte Mabille¹, Adeline Ruyssen Witrand², Thomas Barnetche^3,4, Arnaud Constantin⁵ and Alain G. Cantagrel⁵, ¹Rheumatology Unit, hopital Purpan, Toulouse, France, ²Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ³rheumatology, Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁴Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁵Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose Anti-TNFs have greatly contributed to improve RA prognosis. Hence, the needs for orthopedic surgery have considerably decreased in the past years. However, surgery, whether…
Abstract Number: 465 • 2014 ACR/ARHP Annual Meeting
18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib
S. Cohen¹, Jeffrey R. Curtis², Roy Fleischmann¹ and Y. Chen³, ¹Metroplex Clinical Research Center, Dallas, TX, ²University of Alabama, Birmingham, AL, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Post-marketing surveillance is an important part of monitoring adverse events (AEs) following the approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor…
Abstract Number: 464 • 2014 ACR/ARHP Annual Meeting
Analysis of Pooled Data from Two Randomized Controlled Trials and Their Open-Label Extensions: Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease
Boulos Haraoui¹, Vivian P. Bykerk², Ronald van Vollenhoven³, Marc de Longueville⁴, Kristel Luijtens⁵, Pauline Ralston⁶ and Arthur Kavanaugh⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴SA Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium, ⁶Giant Professional Ltd, London, United Kingdom, ⁷University of California San Diego, La Jolla, CA
Background/Purpose Certolizumab pegol (CZP) is approved for adult patients (pts) with rheumatic diseases (RA, PsA and AS) at a maintenance dose of 200mg every 2…
Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Jonathan Kay¹, Roy Fleischmann², Edward C. Keystone³, Elizabeth C. Hsia^4,5, Neil Goldstein⁴, Benjamin Hsu⁴, Yiying Zhou⁴, Jürgen Braun⁶ and Arthur Kavanaugh⁷, ¹UMass Memorial Medical Center, Worcester, MA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷University of California San Diego, La Jolla, CA
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…
Abstract Number: 472 • 2014 ACR/ARHP Annual Meeting
Abatacept Can be Used Safely for RA Patients with Interstitial Lung Disease
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake³ and Katsutoshi Ando⁴, ¹[email protected], Kameda Medical Center, Kamogawa City, Japan, ²[email protected], Kameda Medical Center, Kamogawa-city, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ⁴Depertment of Respiratoly Medicine, Juntendo university, tokyo, Japan
Background/Purpose : Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of…
Abstract Number: 446 • 2014 ACR/ARHP Annual Meeting
Immunoglobulin a Antibodies to Cyclic Citrullinated Protein Predominate in Individuals at-Risk for Future Rheumatoid Arthritis
Gregory M. Ingolia¹, M. Kristen Demoruelle², Mark C. Parish², Ryan W. Gan³, Jason R. Kolfenbach², Michael H. Weisman⁴, Jane H. Buckner⁵, Peter K. Gregersen⁶, Ted R. Mikuls⁷, James R. O'Dell⁸, Richard M. Keating⁹, Alvin Yee¹⁰, Michael Mahler¹⁰, Jill M. Norris³, Kevin D. Deane² and V. Michael Holers¹¹, ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Scripps Clinic, La Jolla, CA, ¹⁰Research, INOVA Diagnostics, San Diego, CA, ¹¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose Immunoglobulin A (IgA) autoantibodies (Abs) to citrullinated proteins (ACPAs) are present in the preclinical period of RA development, a finding that suggests a mucosal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].